<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01691547</url>
  </required_header>
  <id_info>
    <org_study_id>116415</org_study_id>
    <nct_id>NCT01691547</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Single Dose, Four Way Cross-over Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol Following Single Inhaled Doses of Umeclidinium/Vilanterol Blend + Fluticasone Furoate, Umeclidinium + Vilanterol, Fluticasone Furoate + Vilanterol and Fluticasone Furoate + Umeclidinium in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, single dose (four inhalations), four-way cross over study in healthy&#xD;
      subjects that will assess the systemic pharmacokinetics (PK) and systemic pharmacodynamics&#xD;
      (PD) of Fluticasone Furoate, (FF), Umeclidinium, (UMEC) and Vilanterol (VI). Study drug will&#xD;
      be delivered through a novel single-step activation dry powder inhaler (NDPI) which has a two&#xD;
      strip configuration. The NDPI will be configured with different combinations of each compound&#xD;
      and also a new blend of UMEC/VI inhalation powder within a single strip of the NDPI device.&#xD;
      Study drug will be administered through the inhaled route to healthy subjects in single doses&#xD;
      (four inhalations). Each subject will receive treatment in a randomized order Treatment A FF&#xD;
      (400 microgram [µg]) and UMEC (500 µg)/VI (100 µg), Treatment B UMEC (500 µg) and VI (100&#xD;
      µg), Treatment C FF (400 µg) and VI (100 µg) and Treatment D FF (400 µg) and UMEC (500 µg)&#xD;
      over four treatment periods. Each treatment period will be separated by a washout of 7 to 21&#xD;
      days. After the four treatment periods, a follow up visit will take place 7 to 21 days&#xD;
      following the final dose of study medication and the maximum duration a subject will be&#xD;
      involved in the study is eighteen weeks.&#xD;
&#xD;
      Pharmacokinetics will be assessed by the measurement of plasma and urine concentrations of&#xD;
      FF, UMEC and VI. Safety and PD will be monitored using blood glucose, serum potassium, heart&#xD;
      rate, 12-lead ECGs and clinical laboratory tests. Plasma samples for PK will be collected&#xD;
      throughout the study, urine, blood glucose, serum potassium, heart rate, 12-lead ECGs and&#xD;
      clinical laboratory tests will be assessed on Day 1 only. AEs will be assessed throughout the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2012</start_date>
  <completion_date type="Actual">March 8, 2013</completion_date>
  <primary_completion_date type="Actual">March 8, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC and Cmax, for each of the treatment groups FF/UMEC/VI, UMEC/VI and FF/VI</measure>
    <time_frame>3 days of each treatment period.</time_frame>
    <description>The PK parameters and plasma concentrations: area under the concentration time-curve (AUC) from time zero to infinity (AUC(0-inf)) or AUC from time zero to last time of quantifiable concentration AUC(0-t') and maximum observed plasma concentration (Cmax) will be derived for each treatment group following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI and FF/VI using the following treatment ratios: FF:FF/UMEC/VI versus FF/VI, UMEC:FF/UMEC/VI versus UMEC/VI, VI: FF/UMEC/VI versus UMEC/VI and VI: FF/UMEC/VI versus FF/VI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf) or AUC(0-t') and Cmax for FF/UMEC/VI and FF/UMEC</measure>
    <time_frame>3 days of each treatment period in which FF+UMEC/VI or FF+UMEC were administered.</time_frame>
    <description>The PK parameters will be derived for FF and UMEC and VI following single inhaled doses (four inhalations) of FF/UMEC/VI and FF/UMEC using the following treatment ratios: UMEC:FF/UMEC/VI versus FF/UMEC and FF:FF/UMEC/VI versus FF/UMEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters: tmax, AUC(0-t), t (last), t1/2, λz, CL/F and V/F for individual component of each treatment group (FF/UMEC/VI, UMEC/VI, FF/VI and FF/UMEC)</measure>
    <time_frame>3 days of each treatment period.</time_frame>
    <description>The plasma PK parameters: time to Cmax (tmax), AUC(0-t), time of last measurable concentration (tlast), and terminal phase half-life (t1/2), elimination rate constant (λz), apparent clearance (CL/F) and apparent volume of distribution (V/F) (data permitting) will be derived for FF and UEMC and VI following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI, FF/VI and FF/UMEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetic parameters: Ae6, Ae10, Ae14, Ae18. Ae24, Ae36, Fe6, Fe10, Fe14, Fe 18, Fe24 and Fe36; urine t1/2 and CLr for UMEC following each treatment group (FF/UMEC/VI, UMEC/VI, and FF/UMEC)</measure>
    <time_frame>Day 1 of each treatment period in which UMEC (single or blended) was administered.</time_frame>
    <description>Urine pharmacokinetic parameters: cumulative amount excreted (Ae) in the time interval Ae6, Ae10, Ae14, Ae18, Ae24, Ae36, percent of dose excreted (þ) in the time interval Fe6, Fe10, Fe14, Fe 18, Fe24 and Fe36; urine half life (urine t1/2) and renal clearance CLr (data permitting) will be assessed for UMEC following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI and FF/UMEC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum and weighted mean change from Baseline supine heart rate (0-4 hour (h))</measure>
    <time_frame>3 days of each treatment period.</time_frame>
    <description>The heart rate of the subjects will be measured following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI, FF/VI and FF/UMEC. Change from Baseline will be calculated as supine heart rate (0-4 h) minus supine heart rate (0-4 h) at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum and weighted mean change from Baseline serum potassium (0-4 h)</measure>
    <time_frame>3 days of each treatment period.</time_frame>
    <description>The serum potassium of the subjects will be measured following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI, FF/VI and FF/UMEC. Change from Baseline will be calculated as serum potassium (0-4 h) minus serum potassium (0-4 h) at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum and weighted mean change from Baseline serum glucose (0-4 h)</measure>
    <time_frame>3 days of each treatment period.</time_frame>
    <description>The blood glucose of the subjects will be measured following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI, FF/VI and FF/UMEC. Change from Baseline will be calculated as blood glucose (0-4 h) minus blood glucose (0-4 h) at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of FF, UMEC and VI</measure>
    <time_frame>18 weeks</time_frame>
    <description>Safety and tolerability parameters include AEs, ECG, vital signs (pulse rate and systolic and diastolic blood pressure) and laboratory assessments include clinical biochemistry and hematological parameters.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>UMEC/VI+FF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UMEC (500 µg)/VI(100 µg) (blended together) and FF (400 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UMEC+VI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UMEC (500 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FF+VI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FF (400 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FF+UMEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FF (400 µg) and UMEC (500 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UMEC /VI</intervention_name>
    <description>Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.</description>
    <arm_group_label>UMEC/VI+FF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UMEC</intervention_name>
    <description>Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.</description>
    <arm_group_label>FF+UMEC</arm_group_label>
    <arm_group_label>UMEC+VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI</intervention_name>
    <description>Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.</description>
    <arm_group_label>FF+VI</arm_group_label>
    <arm_group_label>UMEC+VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF</intervention_name>
    <description>Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.</description>
    <arm_group_label>FF+UMEC</arm_group_label>
    <arm_group_label>FF+VI</arm_group_label>
    <arm_group_label>UMEC/VI+FF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation&#xD;
&#xD;
          -  Male or female between 18 and 65 years of age&#xD;
&#xD;
          -  Body Mass Index (BMI) within the range 19.0 - 33.0 kilogram (kg)/meters (m)^2&#xD;
             (inclusive)&#xD;
&#xD;
          -  Average QT interval corrected using Fridericia's (QTcF) formula &lt; 450 millisecond&#xD;
             (msec)&#xD;
&#xD;
          -  Forced Expiratory Volume in 1 second (FEV1) &gt;=80% predicted and a FEV1/Forced Vital&#xD;
             Capacity (FVC) ratio &gt;=0.7&#xD;
&#xD;
          -  Subjects who are current non-smokers who have not used any tobacco products in the&#xD;
             6-month period preceding the screening visit&#xD;
&#xD;
          -  Alanine transaminase (ALT), alkaline phosphatase and bilirubin &lt;=1.5xupper limit of&#xD;
             normal (ULN) (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated&#xD;
             and direct bilirubin &lt;35%)&#xD;
&#xD;
          -  A female subject is eligible to participate if she is confirmed postmenopausal or&#xD;
             permanently sterilized; or if she is of child-bearing potential and is abstinent or&#xD;
             agrees to use contraception prior to start of dosing until the follow up visit&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A supine mean heart rate outside the range 40-90 beats per minute (bpm) at screening.&#xD;
&#xD;
          -  History of respiratory disease (i.e. history of asthmatic symptoms) in the last 10&#xD;
             years.&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening or a positive test for human immunodeficiency&#xD;
             virus (HIV) antibody.&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones) or a history of&#xD;
             regular alcohol consumption within 6 months of the study defined as: an average weekly&#xD;
             intake of &gt;14 drinks for males or &gt;7 drinks for females.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer) or has had exposure to more than four&#xD;
             new chemical entities within 12 months prior to the first dosing day.&#xD;
&#xD;
          -  Lactating or pregnant females as determined by positive serum or urine human chorionic&#xD;
             gonadotropin (hCG) test at screening or prior to dosing.&#xD;
&#xD;
          -  Unable to refrain from the use of prescription or non-prescription drugs, including&#xD;
             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or&#xD;
             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication, unless in the opinion of the&#xD;
             Investigator and Glaxo SmithKline (GSK) Medical Monitor the medication will not&#xD;
             interfere with the study procedures or compromise subject safety. Or the subject is&#xD;
             unable to refrain from consumption of red wine, seville oranges, grapefruit or&#xD;
             grapefruit juice and pummelos, exotic citrus fruits, grapefruit hybrids or fruit&#xD;
             juices from 7 days prior to the first dose of study medication and for the duration of&#xD;
             the study.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>September 20, 2012</study_first_submitted>
  <study_first_submitted_qc>September 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2012</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW642444 (Vilanterol)</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>GSK573719 (Umeclidinium)</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>GW685698 (Fluticasone Furoate)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>116415</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116415</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116415</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116415</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116415</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116415</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116415</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01691547
org study id: 116415
nct id: NCT01691547
lead sponsor: 
collaborator: 
has dmc: No
This is a double-blind, single dose (four inhalations), four-way cross over study in healthy
      subjects that will assess the systemic pharmacokinetics (PK) and systemic pharmacodynamics
      (PD) of Fluticasone Furoate, (FF), Umeclidinium, (UMEC) and Vilanterol (VI). Study drug will
      be delivered through a novel single-step activation dry powder inhaler (NDPI) which has a two
      strip configuration. The NDPI will be configured with different combinations of each compound
      and also a new blend of UMEC/VI inhalation powder within a single strip of the NDPI device.
      Study drug will be administered through the inhaled route to healthy subjects in single doses
      (four inhalations). Each subject will receive treatment in a randomized order Treatment A FF
      (400 microgram [µg]) and UMEC (500 µg)/VI (100 µg), Treatment B UMEC (500 µg) and VI (100
      µg), Treatment C FF (400 µg) and VI (100 µg) and Treatment D FF (400 µg) and UMEC (500 µg)
      over four treatment periods. Each treatment period will be separated by a washout of 7 to 21
      days. After the four treatment periods, a follow up visit will take place 7 to 21 days
      following the final dose of study medication and the maximum duration a subject will be
      involved in the study is eighteen weeks.

      Pharmacokinetics will be assessed by the measurement of plasma and urine concentrations of
      FF, UMEC and VI. Safety and PD will be monitored using blood glucose, serum potassium, heart
      rate, 12-lead ECGs and clinical laboratory tests. Plasma samples for PK will be collected
      throughout the study, urine, blood glucose, serum potassium, heart rate, 12-lead ECGs and
      clinical laboratory tests will be assessed on Day 1 only. AEs will be assessed throughout the
      study.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Other
masking: Double (Participant, Investigator)
measure: AUC and Cmax, for each of the treatment groups FF/UMEC/VI, UMEC/VI and FF/VI
time frame: 3 days of each treatment period.
description: The PK parameters and plasma concentrations: area under the concentration time-curve (AUC) from time zero to infinity (AUC(0-inf)) or AUC from time zero to last time of quantifiable concentration AUC(0-t') and maximum observed plasma concentration (Cmax) will be derived for each treatment group following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI and FF/VI using the following treatment ratios: FF:FF/UMEC/VI versus FF/VI, UMEC:FF/UMEC/VI versus UMEC/VI, VI: FF/UMEC/VI versus UMEC/VI and VI: FF/UMEC/VI versus FF/VI.
measure: AUC(0-inf) or AUC(0-t') and Cmax for FF/UMEC/VI and FF/UMEC
time frame: 3 days of each treatment period in which FF+UMEC/VI or FF+UMEC were administered.
description: The PK parameters will be derived for FF and UMEC and VI following single inhaled doses (four inhalations) of FF/UMEC/VI and FF/UMEC using the following treatment ratios: UMEC:FF/UMEC/VI versus FF/UMEC and FF:FF/UMEC/VI versus FF/UMEC.
measure: Plasma PK parameters: tmax, AUC(0-t), t (last), t1/2, λz, CL/F and V/F for individual component of each treatment group (FF/UMEC/VI, UMEC/VI, FF/VI and FF/UMEC)
time frame: 3 days of each treatment period.
description: The plasma PK parameters: time to Cmax (tmax), AUC(0-t), time of last measurable concentration (tlast), and terminal phase half-life (t1/2), elimination rate constant (λz), apparent clearance (CL/F) and apparent volume of distribution (V/F) (data permitting) will be derived for FF and UEMC and VI following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI, FF/VI and FF/UMEC.
measure: Urine pharmacokinetic parameters: Ae6, Ae10, Ae14, Ae18. Ae24, Ae36, Fe6, Fe10, Fe14, Fe 18, Fe24 and Fe36; urine t1/2 and CLr for UMEC following each treatment group (FF/UMEC/VI, UMEC/VI, and FF/UMEC)
time frame: Day 1 of each treatment period in which UMEC (single or blended) was administered.
description: Urine pharmacokinetic parameters: cumulative amount excreted (Ae) in the time interval Ae6, Ae10, Ae14, Ae18, Ae24, Ae36, percent of dose excreted (þ) in the time interval Fe6, Fe10, Fe14, Fe 18, Fe24 and Fe36; urine half life (urine t1/2) and renal clearance CLr (data permitting) will be assessed for UMEC following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI and FF/UMEC
measure: Maximum and weighted mean change from Baseline supine heart rate (0-4 hour (h))
time frame: 3 days of each treatment period.
description: The heart rate of the subjects will be measured following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI, FF/VI and FF/UMEC. Change from Baseline will be calculated as supine heart rate (0-4 h) minus supine heart rate (0-4 h) at Baseline.
measure: Minimum and weighted mean change from Baseline serum potassium (0-4 h)
time frame: 3 days of each treatment period.
description: The serum potassium of the subjects will be measured following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI, FF/VI and FF/UMEC. Change from Baseline will be calculated as serum potassium (0-4 h) minus serum potassium (0-4 h) at Baseline.
measure: Maximum and weighted mean change from Baseline serum glucose (0-4 h)
time frame: 3 days of each treatment period.
description: The blood glucose of the subjects will be measured following single inhaled doses (four inhalations) of FF/UMEC/VI, UMEC/VI, FF/VI and FF/UMEC. Change from Baseline will be calculated as blood glucose (0-4 h) minus blood glucose (0-4 h) at Baseline.
measure: Safety and tolerability of FF, UMEC and VI
time frame: 18 weeks
description: Safety and tolerability parameters include AEs, ECG, vital signs (pulse rate and systolic and diastolic blood pressure) and laboratory assessments include clinical biochemistry and hematological parameters.
arm group label: UMEC/VI+FF
arm group type: Experimental
description: UMEC (500 µg)/VI(100 µg) (blended together) and FF (400 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
arm group label: UMEC+VI
arm group type: Experimental
description: UMEC (500 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
arm group label: FF+VI
arm group type: Experimental
description: FF (400 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
arm group label: FF+UMEC
arm group type: Experimental
description: FF (400 µg) and UMEC (500 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
intervention type: Drug
intervention name: UMEC /VI
description: Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
arm group label: UMEC/VI+FF
intervention type: Drug
intervention name: UMEC
description: Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
arm group label: FF+UMEC
arm group label: UMEC+VI
intervention type: Drug
intervention name: VI
description: Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
arm group label: FF+VI
arm group label: UMEC+VI
intervention type: Drug
intervention name: FF
description: Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
arm group label: FF+UMEC
arm group label: FF+VI
arm group label: UMEC/VI+FF
criteria: 
gender: All
minimum age: 18 Years
maximum age: 65 Years
healthy volunteers: Accepts Healthy Volunteers
last name: GSK Clinical Trials
role: Study Director
affiliation: GlaxoSmithKline
facility: 
country: United States
url: https://www.clinicalstudydatarequest.com
description: Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
responsible party type: Sponsor
mesh term: Pulmonary Disease, Chronic Obstructive
sharing ipd: Yes
ipd description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
study doc: 
study doc: 
study doc: 
study doc: 
study doc: 
study doc: 
study doc: 